Unknown

Dataset Information

A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy.


ABSTRACT:

Background

Immunotherapy has emerged as an efficient therapeutic approach for cancer management. However, stimulation of host immune system against cancer cells often fails to achieve promising clinical outcomes mainly owing to the immunosuppressive characteristics of the tumor microenvironment (TME). Combination therapeutics that can trigger sustained immunogenic cell death (ICD) have provided new opportunities for cancer treatment.

Methods

In this study, we designed and applied an ICD inducer regimen, including a genetically engineered oncolytic virus (miRNA-modified coxsackieviruses B3, miR-CVB3), a pore-forming lytic peptide (melittin, found in bee venom), and a synthetic toll-like receptor 9 ligand (CpG oligodeoxynucleotides), for breast cancer and melanoma treatment. W

SUBMITTER: Bahreyni A 

PROVIDER: S-EPMC10210435 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature